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Aim: To evaluate the effect of interleukin-6 inhibition with tocilizumab on the cytokine 
network in patients with acute non-ST-elevation myocardial infarction (NSTEMI). 
Methods: 117 patients with acute NSTEMI were randomised to an intravenous infusion of 
280 mg tocilizumab or placebo prior to coronary angiography. Blood samples were obtained 
at baseline, at 6 consecutive timepoints during hospitalisation, and during follow-up. 
Cytokines (n=27) were analysed at all timepoints using a multiplex cytokine assay. 
Results: Using a mixed between-within subjects analysis of variance, we observed a 
significant (p<0.001) tocilizumab*time interaction for interferon gamma-inducible protein 
(IP-10) and macrophage inflammatory protein-1β (MIP-1β) during hospitalisation, due to 
significant increases in the tocilizumab group for both IP-10 (median change from baseline 
during hospitalisation (mΔ), placebo: 3 (-60) pg/ml vs tocilizumab: 209 (69) pg/ml) and MIP-
1β (mΔ, placebo: 5 (-2.1) pg/ml vs tocilizumab 39 (24) pg/ml) compared to placebo, and 
significant between-group differences in changes from baseline (p<0.001) at all timepoints. 
MIP-1β was inversely correlated to troponin T (r=-0.28, p<0.05) and neutrophils (r=-0.32, 
p<0.05) in the tocilizumab group during hospitalisation. 
Conclusions: Tocilizumab led to a substantial increase in IP-10 and MIP-1β during the acute 
phase of NSTEMI. This increase was selective, since none of the other cytokines were 







 Inflammation plays a crucial role in atherogenesis both in the chronic phase, but also 
during plaque rupture with subsequent development of complications like myocardial 
infarction (MI) and ischemic stroke.[1] MI could again trigger a comprehensive inflammatory 
response characterised by homing of leukocytes to the infarcted myocardium and 
upregulation of several cytokines and chemokines.[2] While this complex and timely 
regulated inflammatory surge seems to be essential for infarct healing and cardiac repair in 
MI,[2] an exaggerated or protracted inflammatory response may contribute to increased 
infarct-size, and this could also include adverse inflammatory responses during ischaemia-
reperfusion (I/R) injury.[3] Thus, modulating inflammation could be an attractive therapeutic 
target in MI with potentially beneficial effects on plaque rupture, I/R injury and infarct size. 
 Interleukin-6 (IL-6) is a multifunctional and pro-inflammatory cytokine which is 
upregulated and appears to hold a central position in the inflammatory response during plaque 
destabilisation[4] and MI.[5] In MI, elevated levels of IL-6 are associated with infarct size 
and an adverse prognosis.[5] Furthermore, IL-6 seems to be involved in myocardial I/R 
injury,[6, 7] and increasing levels of IL-6 also predict adverse left ventricular (LV) 
remodeling after acute MI.[8] In the inflammatory response during MI, IL-6 represents an 
intermediate cytokine which is strongly induced by apical cytokines such as IL-1 and tumor 
necrosis factor (TNF),[9] while it is the major inducer of downstream acute phase responses, 
including hepatic production of C-reactive protein (CRP).[10] 
 We have recently shown that IL-6 inhibition by a single intravenous administration of 
280 mg of the IL-6 receptor (R) antagonist tocilizumab attenuated inflammation and 
percutaneous coronary intervention (PCI)-related troponin T (TnT) release in patients with 
non-ST-elevation MI (NSTEMI).[7] These results could suggest a beneficial effect of IL-6 
inhibition on inflammatory mediated I/R injury in these patients. However, cytokines operate 
in complex networks, and the ability of tocilizumab to affect other inflammatory and anti-
inflammatory mediators with relevance to NSTEMI is at present not known. In this pre-
defined sub-study, we sought to evaluate the effects of IL-6 inhibition on the cytokine 
network in patients with acute NSTEMI by analysing a wide range of circulating cytokines 
during hospitalisation and follow-up (i.e. 3 and 6 months post-MI). Furthermore, a dose of 
280 mg of tocilizumab provides total IL-6 blockade for 2-3 weeks,[11] and it is important to 
explore to which extent IL-6 inhibition affects different actors in the cytokine network not 




Study population and design 
This pre-defined sub-study was part of a two-center, randomised, double-blind, 
placebo-controlled trial investigating the effect of a single dose of the anti-IL-6R antagonist 
tocilizumab in patients with NSTEMI scheduled for coronary angiography 
(ClinicalTrials.gov, NCT01491074). The study was performed at Oslo university hospital 
Rikshospitalet, Oslo, and St. Olavs hospital, Trondheim, Norway. The study was approved by 
the Regional Committee for Medical and Health Research Ethics of South-Eastern Norway 
and the Norwegian Medicines Agency, and conducted according to the Helsinki Declaration. 
All participants provided written, informed consent. 
The study design has been reported previously.[7] In short, patients with acute 
NSTEMI presumed to be caused by coronary artery disease (CAD) were included on the day 
of scheduled coronary angiography. Major exclusion criteria were other clinically significant 
heart disease, clinical instability, medication or diseases affecting inflammation, and any 
condition that could interfere with protocol adherence. After baseline blood sampling, patients 
received a 1 hour infusion containing either 280 mg tocilizumab or matching placebo (100 
mL 0.9% NaCl) intravenously, prior to coronary angiography. After coronary angiography 
and percutaneous coronary intervention (PCI) when appropriate, further blood samples were 
obtained at six consecutive timepoints during hospitalisation (day 1: evening, day 2: morning, 
afternoon, evening, day 3: morning, afternoon). Blood samples were also obtained at 3 and 6 
months follow-up. 
Details on randomisation, treatment allocation, drug administration and pharmacology 
are reported elsewhere.[7] 
Blood sampling protocol 
Peripheral venous blood was drawn into endotoxin free blood collection tubes with 
EDTA as anticoagulant (plasma) and with no additives (serum). The EDTA tubes were 
immediately placed on melting ice and centrifuged within 30 minutes at >2500 × g for 20 
minutes to obtain platelet-poor plasma. Serum was centrifuged at >2100 × g for 15 minutes 
after full coagulation (~45 minutes) in room temperature. Immediately following 
centrifugation, both plasma and serum aliquots were stored at -80°C until analyses in multiple 
aliquots. Samples were thawed only once. 
Biochemical analyses 
 Components of the cytokine network were analysed in plasma according to the 
manufacturer’s protocol using a multiplex cytokine assay (Bio-Plex Pro™ Human Cytokine 
Plex-27 Assay, Bio-Rad Laboratories, Hercules, CA) analyzing IL-1β, IL-1 receptor 
antagonist (IL-1ra), IL-2, IL-4, IL-5, IL-6, IL-7, IL-8/CXCL-8, IL-9, IL-10, IL-12 (p70), IL-
13, IL-15, IL-17, basic fibroblast growth factor (bFGF), granulocyte colony-stimulating factor 
(G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), interferon-gamma 
(IFN-ɣ), eotaxin/CCL11, IFN-ɣ-inducible protein (IP-10)/CXCL10, macrophage 
chemoattractant protein (MCP-1)/CCL2, macrophage inflammatory protein-1α (MIP-
1α/CCL3), MIP-1β/CCL4, regulated on activation, normal T-cell expressed and secreted 
(RANTES)/CCL5, tumor necrosis factor (TNF), platelet-derived growth factor (PDGF), and 
vascular endothelial growth factor (VEGF). Inter-assay and intra-assay co-efficient of 
variations were <15 and <11 for all analytes, respectively. 
 High-sensitivity C-reactive protein (hsCRP) was analysed on a MODULAR platform 
(Roche Diagnostics, Basel, Switzerland), and high-sensitivity troponin T (hsTnT) was 
measured by electrochemiluminescence immunoassay (ELICA; Elecsys 2010 analyzer, Roche 
Diagnostics). Leukocytes with subgroups were analysed consecutively using routine methods 
at the hospitals’ clinical biochemistry laboratories.  
Endpoints 
The main endpoint was to evaluate any differential effects of tocilizumab treatment on 
27 different components of the cytokine network in patients with acute NSTEMI during 
hospitalisation, by the presence of a significant tocilizumab*time interaction. Secondary 
endpoints were differential effects of tocilizumab treatment on components of the cytokine 
network at 3 and 6 months follow-up, and if there were any within-group changes in levels at 
follow-up visits compared to baseline. We also evaluated associations between cytokines 
significantly affected by tocilizumab treatment and hsCRP, hsTnT and IL-6. 
Statistics 
The statistical analyses were performed with a per-protocol approach. IL-2, IL-15 and 
PDGF had in total (of all values in 117 patients over all timepoints) >10 % values out-of-
lower-range (OOR) and were left out of further statistical analyses. For IL-8, 15 % of the 
samples had to be excluded due to technical problems with one of the plates, and analyses 
could unfortunately not be repeated. To avoid loss of low level data, values OOR and values 
<1.0 pg/ml were set to 1.0 pg/ml for all cytokines included in further statistical analyses, 
except for IL1-β for which values OOR and <0.5 pg/ml were set to 0.5 pg/ml. Further details 






121 patients with NSTEMI were enrolled between August 2011 and November 2013. 
Follow-up ended in April 2014. Of these, 117 patients were included in the final analyses. 
There were no between-group differences in baseline characteristics (Table 1). Details 
regarding the screening and inclusion process, and dropout of patients (placebo n=3, 
tocilizumab n=3) are described previously.[7] 
Cytokine network during hospitalisation 
We have previously reported a significant increase during hospitalisation for IL-6 in 
the tocilizumab group for these patients,[7] as also replicated using the IL-6 multiplex assay 
in the current study (Figure 1, Table 2). Furthermore, we also observed a similar highly 
significant tocilizumab*time interaction for IP-10 and MIP-1β during hospitalisation (Figure 
1, Table 2). Both cytokines were stable during hospitalisation in the placebo group, whereas a 
rapid and substantial increase was observed in the tocilizumab group. Furthermore, a more 
subtle, but significant tocilizumab*time interaction was observed for IL-8, reflecting a fall in 
the placebo group and no increase in the tocilizumab group (Figure 1, Table 2).  
For the other evaluated cytokines no between-group significant impact of tocilizumab 
was observed (Table 2).  
Cytokine network at 3 and 6 months follow-up 
Except for a modest between-group difference for bFGF, there were no significant 
between-group differences in patterns of change from baseline for other cytokines at 3 and 6 
months follow-up (Table 3). In both treatment groups, with a few exceptions, levels of 
cytokines were significantly lower at both 3 and 6 months follow-up compared to baseline. 
However, levels of IP-10 increased significantly compared to baseline in both groups at 3 
months follow-up, whereas levels were comparable to baseline at 6 months. Also, in both 
groups, there were no significant changes in levels of MIP-1β compared to baseline at 3 and 6 
months follow-up. 
Impact of revascularisation therapy on cytokine levels during hospitalisation 
The effects of tocilizumab on IP-10 and MIP-1β, as well as previously described for 
IL-6,[7] were not affected by revascularisation therapy (PCI performed vs PCI not performed) 
(Supplementary Tables S1 and S2). However, while there was no between-group difference 
during hospitalisation for IL-8 in patients treated with PCI, a significant tocilizumab*time 
interaction was observed for IL-8 in patients not treated with PCI, reflecting a decrease in IL-
8 in the placebo group (Supplementary Table S2). 
Impact of time from symptom onset on cytokine levels during hospitalisation 
 Also for patients included ≤2 days (early) from symptom onset, the same between-
group differences as for all patients were observed for IP-10 and MIP-1β as well as for IL-
6,[7] but not for IL-8 (Supplementary Table S3). However, in patients included >2 days (late) 
from symptom onset, equivalent significant between-group differences were observed for 
MIP-1β only, in addition to IL-6, but not for IL-8 or IP-10 (Supplementary Table S4).  
Correlations between IP-10, MIP-1β and IL-6, hsCRP, leukocytes and hsTnT during 
hospitalisation 
 We have previously shown that tocilizumab treatment caused a significant attenuation 
of CRP levels and PCI-related TnT release, as well as a substantial rise in IL-6 levels 
(reflecting attenuated elimination, but decreased IL-6 bioacitvity), and a profound decrease in 
neutrophils during hospitalisation in these patients.[7] There were no associations between 
area under the curve (AUC) for IL-6 and AUCs for IP-10 or MIP-1β in either treatment group 
during hospitalisation (Table 4). However, there was a significant positive association 
between AUCs for IP-10 and CRP in the placebo group, and significant inverse associations 
between AUCs for MIP-1β and AUCs for neutrophils and TnT (Table 4). 
Discussion 
 We have previously shown that IL-6 inhibition with tocilizumab attenuated 
inflammation and PCI-related TnT-release in patients with NSTEMI.[7] In this pre-defined 
sub-study, we explored the effects of tocilizumab on the cytokine network in these patients. 
Our main findings were; (i) Most cytokines remained unaffected by tocilizumab treatment. 
(ii) However, tocilizumab led to a profound and selective increase in IP-10 and MIP-1β, 
whereas the effect on IL-8 was more complex. Overall, tocilizumab seemed to exert modest 
and selective effects on the universal inflammatory surge during the acute phase of NSTEMI, 
and the causes and implications of the elevated levels of especially IP-10 and MIP-1β requires 
further attention in forthcoming studies. 
 Whereas most analysed cytokines were elevated during hospitalisation as compared 
with follow-up, there was somewhat surprisingly no effect of tocilizumab on these mediators, 
except for IP-10, MIP-1β and IL-8. There are some in vitro studies showing that tocilizumab 
inhibits TNF[12] and other inflammatory cytokines,[13] and tocilizumab has been reported to 
down-regulate IL-21 in humans.[14] There is also one study showing that tocilizumab down-
regulates several inflammatory cytokines in patients with rheumatoid arthritis (ref), but this 
study had no placebo group. The present study is, however, to the best of our knowledge, the 
first report on the effect of tocilizumab on the cytokine network in a placebo-controlled 
randomised trial in humans. It has been claimed that IL-6 functions primarily as a secondary 
signaling cytokine, with a rather narrow effect on the cytokine network (ref), and the present 
study could support such a notion. However, tocilizumab markedly down-regulated CRP in 
patients in the present study.[7] 
 In contrast to most of the examined cytokines, tocilizumab had a significant effect on 
IP-10 and MIP-1β, with increasing levels of both cytokines during IL-6R blockade. The 
potential consequences of these effects, if any, is at present unclear, but some possibilities 
exist. IP-10 is a chemokine which is known to be upregulated during MI.[15, 16] A role of IP-
10 in I/R-injury in MI has been suggested, possibly related to effects on leukocyte 
subpopulations.[15] However, previous studies have so far reported conflicting results 
regarding IP-10’s association with infarct size in patients with reperfused MI,[15, 16] and 
there were no associations between IP-10 and TnT levels during hospitalisation in either of 
the groups in the present study. Thus, the current body of evidence does not provide 
compelling evidence that IP-10 holds a central position in the inflammatory arm of I/R-injury, 
and the potentially cardioprotective effect of IL-6 inhibition in patients with NSTEMI in the 
present study,[7] does not appear to be mediated via this chemokine. However, in an 
experimental study on mice undergoing myocardial I/R protocols, IP-10 deficient mice 
experienced accentuated LV remodeling compared to controls, which seem contradictory to 
the notion that suppression of IP-10 is essential to counteract LV remodeling following 
MI.[17] Thus, neither previous data nor the present study provide convincing evidence that 
high levels of IP-10 are either beneficial or clearly harmful during MI.  
 MIP-1β is a chemokine which seems to be upregulated in MI and to be involved in 
leukocyte recruitment to the infarcted myocardium.[18] Previously, levels of MIP-1β has 
been shown to be positively correlated to infarct size in patients with reperfused MI, which in 
turn could indicate an unfavourable role in I/R injury.[15] On the other hand, in a rat 
myocardial I/R-model, MIP-1β and signaling through on of its receptors CCR5, seemed to 
restrain postinfarction inflammation and the adverse LV remodeling through increased 
myocardial recruitement of T regulatory cells.[18] Herein, MIP-1β was substantially 
increased during hospitalisation in patients treated with tocilizumab. We have previously 
reported that tocilizumab caused a profound decrease in neutrophil counts during 
hospitalisation.[7] This phenomenon may be involved in the potentially cardioprotective 
effect of IL-6 inhibition reflected by attenuated TnT release in these patients.[7] Interestingly, 
MIP-1β was inversely correlated to both TnT and neutrophils in the tocilizumab group. Thus, 
the inverse correlation between elevated levels of MIP-1β and neutrophils in tocilizumab 
treated patients, may suggest that MIP-1β is involved in tocilizumab’s suppressive and 
potentially beneficial effect on neutrophil counts. However, it is also possible that the inverse 
correlation between MIP-1β and neutrophils could reflect that this chemokine is directing the 
leukocytes into the myocardium, away from the circulation, and thereby mediating harmful 
effects.  
 This study has some limitations. The conspicuously absent effect of IL-6 inhibition on 
the majority of components in the cytokine network, might be due to the wide distribution in 
time from symptom onset to inclusion in this study, as patients could have been included at a 
time when the primary myocardial injury already had occurred. Furthermore, plasma levels do 
not necessarily reflect cytokine levels at the site of inflammation and it is possible that 
tocilizumab could have a broader effect within the myocardium and the coronary plaque. 
Finally, associations do not prove any causal relationship and more mechanistic studies are 
needed to elucidate the effects of IL-6 inhibition in NSTEMI. 
 Inflammation plays a crucial role in the pathogenesis of atherosclerosis, plaque rupture 
and MI, and there is an urgent need for treatment modalities that are targeting the 
inflammatory arm of atherogenesis, I/R-injury and cardiac repair mechanisms after MI. This 
study shows that a single dose of the IL-6R antagonist tocilizumab selectively increased IP-10 
and MIP-1β levels in NSTEMI patients during hospitalisation, with no effects on the other 
cytokines. Further studies are needed to clarify the role of IP-10 and MIP-1β during NSTEMI, 
and forthcoming studies should also address through what mechanisms tocilizumab attenuates 
TnT release in these patients. The limited impact of IL-6 inhibition on the cytokine network in 
these patients, could suggest that the beneficial effects may be caused by effects directly 
related to IL-6, or mediated through CRP, possibly underscoring the pivotal role of this 
cytokine in post-MI inflammation. 
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Table 1. Baseline Characteristics according to Treatment Group 
 
 Placebo (n=59) Tocilizumab (n=58) P-Value 
    
 
Age, y, mean (SD) 60.1 (9.9) 59.8 (7.7) 0.859 
    
Female, n (%) 5 (8.5) 9 (15.5) 0.364 
    
Body mass index, kg/m2, mean (SD) 27.4 (4.4) 28.8 (3.3) 0.055 
    
Blood pressure, systolic, mm Hg, mean (SD) 136.8 (18.0) 139.7 (18.1) 0.389 
    
Blood pressure, diastolic, mmHg, mean (SD) 80.5 (12.1) 82.9 (12.0) 0.273 
    
Hypertension, n (%) 17 (28.8) 26 (44.8) 0.109 
    
Diabetes Mellitus, n (%) 10 (16.9) 11 (19.0) 0.966 
    
Current Smoking, n (%) 17 (28.8) 15 (26.3) 0.926 
    
Previous Myocardial Infarction, n (%) 7 (11.9) 9 (15.5) 0.760 
    
GRACE score, mean (SD) 90.3 (20.2) 86.3 (19.1) 0.272 
    
 
Symptom onset to inclusion, days, median 
(25th, 75th percentiles)  
2 (1, 3) 2 (1, 3.5) 0.197 
    
 
Maximum TnT before baseline, ng/L, n=85, geometric mean (CI) 310 (214-449) 334 (217-514) 0.789 
    
Maximum TnI before baseline, ng/L, n=31, geometric mean (CI) 1571 (517-4773) 2221 (826-5976) 0.626 
    
 
Aspirin, n (%) 59 (100) 57 (98.3) 0.496 
    
Clopidogrel, n (%) 32 (54.2) 32 (55.2) 1.0 
    
Ticagrelor, n (%) 27 (45.8) 26 (44.8) 1.0 
    
Low molecular weight heparin, n (%) 54 (91.5) 51 (89.5) 0.952 
    
Statin, n (%) 53 (89.8) 53 (91.4) 1.0 
    
Betablocker, n (%) 45 (76.3) 45 (77.6) 1.0 
    
 
PCI, n (%) 47 (79.7) 41 (70.7) 0.367 
    
Stents per PCI-treated patient, mean (SD) 1.85 (1.28) 1.85 (1.15) 0.982 
    
CABG, n (%) 7 (11.9) 6 (10.3) 1.0 
    
Medical treatment, n (%) 5 (8.5) 11 (19.0) 0.167 
    
SYNTAX score,  median 
(25th, 75th percentiles) 
8.0 (5, 14) 8.0 (4, 18) 0.629 
    
 
TnT, troponin T; TnI, troponin I; PCI, percutaneous coronary intervention; CABG, Coronary Artery Bypass Grafting 
Table 2. Multiplex cytokine assay in patients with non-ST-elevation myocardial infarction receiving placebo (n=59) and tocilizumab (n=58).  
Cytokine 
(pg(mL) 
Group Baseline Evening day 1 Morning day 2 Afternoon day2 Evening day 2 Morning day 3 Afternoon day 3 Repeated 
measures, P† 
IL-1β 
Placebo 5.8 (2.9,9.7) 3.0 (1.3,5.1) 5.9 (2.8,8.1) 4.3 (2.0,7.2) 3.5 (1.3,5.7) 3.9 (2.2,7.5) 3.5 (2.1,5.7) 
0.151 
Tocilizumab 4.8 (2.0,10.2) 4.2 (1.6,6.1) 4.3 (2.2,8.0) 4.1 (2.1,6.8) 4.1 (1.6,7.0) 4.8 (2.1,8.2) 3.3 (1.8,6.7) 
IL-1ra 
Placebo 113 (73-176) 76 (52-111) 115 (86-155) 99 (71-139) 80 (55-116) 82 (57-118) 85 (60-122) 
0.657 
Tocilizumab 147 (103-210) 98 (71-134) 112 (85-148) 109 (83-143) 104 (75-144) 94 (69-129) 98 (73-130) 
IL-4 
Placebo 4.4 (2.4,6.2) 2.8 (1.0,4.7) 4.1 (2.2,5.3) 3.4 (2.2,5.1) 3.0 (1.2,4.7) 3.1 (1.9,4.9) 3.2 (1.7,4.6) 
0.353 
Tocilizumab 4.1 (2.1,6.6) 3.3 (1.7,4.7) 3.3 (2.0,5.5) 3.6 (2.0,4.9) 3.3 (1.8,4.8) 2.8 (2.1,5.1) 3.1 (1.7,4.7) 
IL-5 
Placebo 21 (12,29) 14 (7,21) 19 (12-25) 17 (10-23) 14 (8-21) 14 (8-22) 13 (10-22) 
0.588 
Tocilizumab 19 (11-29) 14 (8-22) 16 (9-23) 16 (9-22) 15 (7-24) 16 (9-20) 13 (7-20) 
IL-6 
Placebo 8 (6-10) 10 (8-12)* 10 (9-13)** 9 (8-11) 8 (6-9) 8 (6-9) 6 (5-8)* 
<0.001 
Tocilizumab 7 (6-9) 37 (29-46)***C 40 (33-50)***C 34 (28-41)***C 36 (30-44)***C 37 (30-45)***C 31 (25-39)***C 
IL-7 
Placebo 26 (21-33) 17 (14-21) 24 (20-30) 22 (17-27) 16 (13-20) 22 (18-28) 19 (15-23) 
0.530 
Tocilizumab 27 (20-34) 19 (15-24) 27 (22-32) 20 (15-26) 18 (15-23) 23 (18-30) 22 (17-27) 
IL-8 
Placebo 16 (10,30) 11 (7,20)*** 17 (10,26) 14 (10,22)** 11 (7,17)*** 13 (8,24)* 12 (8,20)*** 
0.019 
Tocilizumab 13 (9,32) 15 (10,22) 16 (11,25) 13 (9,22) 13 (9,21) 15 (10,25) 13 (10,22) 
IL-9 
Placebo 16 (12-22) 10 (8-13) 16 (13-21) 14 (11-18) 10 (7-13) 14 (10-19) 11 (8-15) 
0.303 
Tocilizumab 18 (13-25) 12 (9-17) 18 (14-23) 14 (10-19) 13 (10-17) 15 (11-21) 15 (11-20) 
IL-10 
Placebo 21 (15-30) 11 (8-16) 20 (15-27) 16 (12-23) 12 (8-16) 16 (12-23) 13 (9-19) 
0.278 
Tocilizumab 22 (15-33) 13 (9-18) 17 (12-23) 13 (9-19) 11 (8-15) 15 (11-21) 14 (10-20) 
IL-12 
Placebo 33 (24-46) 18 (13-24) 31 (24-41) 25 (19-34) 18 (13-25) 26 (18-37) 21 (15-28) 
0.343 
Tocilizumab 32 (23-45) 19 (14-26) 27 (21-35) 21 (16-29) 18 (13-24) 24 (18-33) 23 (17-32) 
IL-13 
Placebo 22 (16-30) 10 (7-15) 17 (13-23) 14 (10-20) 10 (7-14) 14 (10-19) 12 (9-17) 
0.407 
Tocilizumab 22 (16-30) 12 (9-17) 16 (13-21) 15 (11-19) 12 (9-15) 14 (11-19) 15 (12-20) 
IL-17 
Placebo 39 (21,68) 24 (8,44) 38 (20,61) 29 (14,57) 27 (11,50) 33 (12,58) 28 (13,46) 
0.204 
Tocilizumab 42 (18,80) 31 (18,57) 39 (19,65) 39 (20,60) 35 (19,52) 37 (18,64) 34 (17,58) 
Eotaxin 
Placebo 91 (66,127) 78 (56,104) 86 (68,120) 95 (64,115) 77 (59,100) 83 (57,109) 75 (58,111) 
0.299 
Tocilizumab 100 (59,157) 84 (56,135) 83 (62,169) 87 (59,168) 84 (59,151) 87 (59,137) 90 (61,147) 
Bas FGF 
Placebo 64 (41,87) 45 (24,62) 64 (37,82) 54 (32,74) 49 (28,73) 51 (32,76) 48 (32,70) 
0.684 
Tocilizumab 63 (36,93) 48 (31,66) 54 (32,80) 57 (29,77) 51 (29,69) 50 (30,78) 52 (29,78) 
G-csf 
Placebo 58 (45-73) 39 (31-49) 55 (45-66) 43 (32-57) 36 (27-49) 42 (32-55) 46 (37-56) 
0.322 
Tocilizumab 61 (50-74) 46 (37-57) 54 (45-46) 50 (42-61) 48 (40-59) 49 (40-61) 51 (42-63) 
GM-csf 
Placebo 57 (25,67) 39 (18,54) 49 (28,68) 45 (24,63) 39 (18,59) 35 (23,63) 40 (20,59) 
0.403 
Tocilizumab 51 (20,82) 40 (19,65) 41 (22,66) 43 (22,63) 40 (18,65) 42 (18,67) 41 (18,58) 
IFN-γ 
Placebo 162 (83,232) 100 (33,168) 161 (75,210) 119 (77,199) 111 (36,184) 116 (57,190) 116 (64,170) 
0.857 
Tocilizumab 138 (69,261) 114 (66,182) 133 (60,211) 124 (68,198) 121 (54,176) 112 (64,216) 117 (59,197) 
IP-10 
Placebo 381 (275,672) 366 (252,561)** 495 (286,783) 431 (257,694) 433 (266,664) 481 (349,741)** 447 (305,757) 
<0.001 
Tocilizumab 421 (282,899) 630 (418,954)***C 754 (477,1289)***C 613 (450,947)***C 587 (429,892)***C 718 (487,1155)***C 556 (384,961)***C 
MCP-1 
Placebo 40 (25,73) 30 (17,47) 41 (24,65) 37 (22,59) 28 (17,53) 33 (20,60) 29 (18,51) 
0.265 
Tocilizumab 40 (20,83) 35 (20,60) 37 (21,65) 35 (20,64) 36 (17,53) 36 (23,65) 31 (17,61) 
MIP-1α 
Placebo 85 (47,131) 57 (29,85) 86 (50,114) 70 (40,104) 58 (29,98) 74 (43,114) 55 (37,98) 
0.491 
Tocilizumab 77 (47,135) 63 (39,100) 72 (44,110) 70 (37,92) 58 (39,84) 74 (40,113) 64 (41,101) 
MIP-1β 
Placebo 61 (54-68) 61 (55-68) 69 (62-77)*** 64 (57-72) 63 (57-71) 75 (67-83)*** 65 (58-72) 
<0.001 
Tocilizumab 59 (54-65) 97 (85-110)***C 113 (101-126)***C 96 (86-107)***C 90 (81-100)***C 108 (97-120)***C 88 (79-98)***C 
RANTES 
Placebo 451 (213,1231) 551 (195,1385) 570 (182,1300) 677 (197,1143) 406 (216,1697) 393 (164,1008) 610 (285,1272) 
0.900 
Tocilizumab 418 (249,1161) 411 (196,896) 366 (211,881) 470 (181,1203) 437 (148,2201) 352 (162,818) 386 (198,1298) 
TNF-α 
Placebo 60 (21,78) 27 (8,51) 49 (16,65) 37 (15,61) 29 (8,60) 29 (15,67) 31 (12,57) 
0.220 
Tocilizumab 46 (16,95) 29 (15,59) 31 (15,70) 31 (15,65) 33 (13,60) 32 (14,69) 29 (13,59) 
VEGF 
Placebo 23 (16-34) 14 (10-19) 23 (17-31) 19 (14-26) 14 (10-20) 18 (13-26) 15 (11-21) 
0.452 
Tocilizumab 24 (17-35) 15 (10-21) 19 (14-26) 17 (12-24) 15 (11-21) 18 (13-25) 18 (13-25) 
 
Data are geometric mean and (95 % confidence interval) and median (25th, 75th percentiles). *p<0.05, **p<0.01, ***p<0.001 vs baseline. Cp<0.001 changes from baseline vs placebo same timepoint. 
†interaction tocilizumab*time in mixed between-within subjects analysis of variance during hospitalisation. 
 
 
Table 3. Multiplex cytokine assay in patients with non-ST-elevation myocardial infarction at baseline and during follow-up receiving placebo (n=59) and tocilizumab (n=58). 
Cytokine (pg/mL) Group Baseline 3 months 6 months Repeated measures, P† 
IL-1β 
Placebo 5.8 (2.6,9.7) 2.9 (1.3,4.3)*** 2,8 (0.7,4.7)*** 
0.617 
Tocilizumab 4.8 (1.9,10.3) 3.0 (1.2,5.0)*** 3.7 (1.1,4.5)*** 
IL-1ra 
Placebo 119 (77-186) 72 (48-108) 78 (47-130) 
0.763 
Tocilizumab 146 (103-205) 72 (46-114)*** 95 (61-148) 
IL-4 
Placebo 4.5 (2.4,6.3) 2.7 (1.0,4.0)*** 2.3 (1.0,4.2)*** 
0.829 
Tocilizumab 4.0 (2.1,6.5) 2.7 (1.0,4.0)*** 2.6 (1.0,4.1)*** 
IL-5 
Placebo 21 (12,29) 14 (6,22)*** 11 (4,23)** 
0.614 
Tocilizumab 20 (11,30) 13 (4,23)*** 12 (4,24)*** 
IL-6 
Placebo 7.7 (6.9,9.8) 3.2 (2.6-3.9)*** 4.3 (3.4-5.4)*** 
0.878 
Tocilizumab 7.5 (5.9-9.5) 3.4 (2.7-4.2)*** 4.5 (3.6-5.6)** 
IL-7 
Placebo 26 (21-32) 11 (9-14)*** 10 (8-13)*** 
0.744 
Tocilizumab 26 (20-33) 13 (10-16)*** 11 (8-14)*** 
IL-8 
Placebo 15 (10,30) 9 (6,13)*** 9 (6,11)*** 
0.763 
Tocilizumab 13 (9,30) 8 (6,12)*** 8 (6,10)*** 
IL-9 
Placebo 16 (12-22) 7 (6-10)*** 6 (5-9) 
0.969 
Tocilizumab 19 (22-26) 8 (6-12)*** 7 (5-10)*** 
IL-10 
Placebo 20 (14-29) 9 (6-12)*** 7 (5-9)*** 
0.784 
Tocilizumab 21 (15-31) 8 (6-12)*** 7 (5-10) 
IL-12 
Placebo 32 (22-45) 15 (11-20)*** 12 (9-15)*** 
0.580 
Tocilizumab 31 (22-43) 13 (9-17)*** 11 (9-15)*** 
IL-13 
Placebo 22 (16-30) 8 (6-10)*** 6 (4-8)*** 
0.625 
Tocilizumab 21 (16-29) 6 (5-9)*** 6 (5-8)*** 
IL-17 
Placebo 38 (21,69) 25 (9,37)*** 22 (7.36)*** 
0.434 
Tocilizumab 42 (18,76) 24 (11,41)*** 26 (8,39)*** 
Eotaxin 
Placebo 91 (65,127) 69 (57,104)*** 72 (59,129)* 
0.884 
Tocilizumab 96 (59,152) 71 (57,124)*** 78 (59,137) 
Bas FGF 
Placebo 64 (38,87) 46 (27,59)*** 38 (20,55)*** 
0.034 
Tocilizumab 63 (36,88) 44 (22,66)** 42 (42,61)*** 
G-csf 
Placebo 57 (45-73) 34 (26-44)** 32 (25-42)*** 
0.501 
Tocilizumab 60 (49-73) 31 (22-43)*** 36 (28-48)*** 
GM-csf 
Placebo 57 (25,67) 33 (13,59)*** 33 (13,57)*** 
0.607 
Tocilizumab 51 (21,82) 40 (14,64)** 39 (19,60)*** 
IFN-γ 
Placebo 162 (80,232) 95 (36,142)*** 107 (34,163)*** 
0.402 
Tocilizumab 138 (69,261) 104 (25,149)*** 116 (28,162)*** 
IP-10 
Placebo 381 (273,672) 464 (318,872)*** 408 (314,1044) 
0.522 
Tocilizumab 420 (276,783) 456 (351,772)** 429 (291,857) 
MCP-1 
Placebo 40 (24,73) 23 (13,37)*** 24 (10,36)*** 
0.496 
Tocilizumab 40 (21,80) 26 (10,44)*** 26 (13,43)** 
MIP-1α 
Placebo 83 (42,131) 44 (33,64)*** 48 (23,58)*** 
0.317 
Tocilizumab 75 (46,132) 45 (31,73)*** 42 (29,61)*** 
MIP-1β 
Placebo 61 (54-68) 58 (52-64) 59 (53-66) 
0.138 
Tocilizumab 59 (55-65) 60 (56-65) 56 (52-61) 
RANTES 
Placebo 460 (262,1231) 342 (190,2137) 491 (166,2324) 
0.533 
Tocilizumab 460 (261,1288) 422 (168,1916) 629 (196,2722) 
TNF-α 
Placebo 60 (21,78) 23 (8,55)*** 31 (12,65)* 
0.765 
Tocilizumab 46 (16,95) 25 (7,61)** 36 (10,69)** 
VEGF 
Placebo 23 (16-33) 11 (8-15)*** 10 (7-14)*** 
0.862 
Tocilizumab 23 (16-33) 12 (9-16)*** 11 (8-14)*** 
Data are geometric mean and (95 % confidence interval), median and (25th, 75th percentiles) and mean (standard deviation). *p<0.05, **p<0.01, ***p<0.001 vs baseline. Ap<0.05, Bp<0.01, Cp<0.001 changes from 
baseline vs placebo same timepoint. †interaction tocilizumab*time in mixed between-within subjects analysis of variance during follow-up. 
 
Table 4. Pearson r correlations between area under the curve during hospitalisation for IP-10, MIP-1β 
and IL-6, CRP, neutrophils and troponin T in patients with non-ST-elevation myocardial infarction. 
Placebo n=59, Tocilizumab n=58. 
 AUC IP-10 AUC MIP-1β 
 Placebo Tocilizumab Placebo Tocilizumab 
AUC IL-6 0.168 -0.129 0.205 -0.111 
AUC CRP 0.346** -0,079 0.061 -0.158 
AUC Neutr 0.208 -0.155 -0.078 -0.321* 
AUC TnT 0.109 -0.077 -0.055 -0.279* 
 
*p<0.05, **p<0.01. IP-10, interferon gamma inducible protein/CXCL10. MIP-1β, macrophage 




Figure 1. Interleukin-6 (IL-6), interferon gamma-inducible protein/CXCL10 (IP-10), 
macrophage inflammatory protein-1β (MIP-1β) (all placebo n=59, tocilizumab n=58), and IL-
8 (placebo n=49, tocilizumab n=46) during hospitalisation in patients with non-ST-elevation 
myocardial infarction. Circles and squares represents geometric means (IL-6 and MIP-1β) and 
median values (IL-8 and IP-10), bars represent 95 % confidence intervals (IL-6 and MIP-1β) 
and 25th and 75th percentiles (IL-8 and IP-10). *p<0.05, **p<0.01, ***p<0.001 vs baseline 
within group. †p<0.001 for between-group differences in changes from baseline at separate 
timepoints. 
 
